Pfizer China "New Head" Peng Zhenke: Decoding New Pfizer Helps Sustainable Development of Medical and Health Industry

　　On November 2nd, after many years of absence, Peng Zhenke returned to China again and assumed the position of President of Pfizer Biopharmaceutical Group China, becoming the new "Head" of Pfizer China
.

　　2021 is the first year of Pfizer's transformation
.
Pfizer is transforming into a science-based, innovative, patient-first biopharmaceutical company, evolving from a strong business organization to a first-class scientific giant
.
However, in the eyes of Peng Zhenke, who has more than 20 years of experience in performing duties in multinational pharmaceutical companies, the pressure of transformation is the driving force for development
.
Peng Zhenke gave his answer on how to transform the company, what development trend the pharmaceutical industry will have in the post-epidemic era, and how Pfizer actively integrates into development and uses practical actions to help "Healthy China 2030"
.

Peng Zhenke, President of Pfizer Biopharmaceutical Group China

　　Innovation is the source of power, leading development and fulfilling promises

　　When asked why he chose to join Pfizer, Peng Zhenke said that Pfizer encourages innovation, values ​​talent development, and is always “patient-centered”, which is in line with its professional ideals and goals
.
Joining Pfizer, Peng Zhenke is determined to lead Pfizer and embark on a "new journey" with his head up
.

　　According to reports, since entering China for more than 30 years, Pfizer has introduced more than 60 innovative drugs, including original research drugs and vaccines, to China, benefiting tens of millions of Chinese patients
.
By 2025, Pfizer will also introduce 24 new products, new indications, and new dosage forms to China to meet the health needs of Chinese patients at all stages of their lives
.
During the 4th China International Import Expo, Pfizer will comprehensively showcase its breakthrough innovative products and achievements in the five areas of cancer, vaccines, anti-infection, inflammation and immunity, and rare diseases
.
Among them, blockbuster new products include loratinib, sugarizumab, 20-valent pneumococcal polysaccharide conjugate vaccine (PCV20), isaconazole sulfate CRESEMBA (Isavuconazole), CIBINQO® (abrocitinib), tofacitib citrate Sustained-release tablets have brought hope to Chinese patients who are in urgent need
.

　　In fact, Pfizer's continuous product innovation stems from its strong research and development capabilities
.
While introducing innovative products, Pfizer also brought R&D technologies and concepts to China to help accelerate the innovative development of China’s local R&D
.
In 2020, Pfizer proposed the "two 80%" strategy, that is, by 2022, China will participate in more than 80% of global early and key clinical research; 80% of the projects will be declared at the same time and will eventually be introduced to China, so that China Participate in Pfizer's global R&D pipeline life cycle as early as possible and more, especially early clinical research projects, so that Chinese patients can get Pfizer's breakthrough and innovative treatments faster
.

　　Pfizer also actively explores digital transformation and incorporates it into Pfizer’s go-to-market model.
Through the establishment of a cross-departmental agile team, "transforms the way we interact with patients and doctors", and provides digital solutions to transform to virtual interactive channels, accelerating Internet healthcare Ecosystem construction
.

　　Facing new changes, mobilizing resources for a win-win cooperation

　　In recent years, with the introduction of a series of favorable policies such as import "zero tariff" and the reform of the drug review and approval system, and the joint promotion of national policies supported by China's innovative drugs, many outstanding local innovative drug R&D companies have emerged
.
The outbreak of the epidemic has led to a blowout of digitalization.
Medical big data, artificial intelligence, and Internet + models.
China's medical ecology is changing rapidly, and a new medical digital ecosystem is gradually taking shape
.
 

　　The impact of the external environment has brought huge challenges to foreign-funded pharmaceutical companies
.
Peng Zhenke said that this is a challenge as well as an opportunity
.
The country advocates the "dual cycle" model, and Pfizer actively integrates into it and proposes a "dual engine" business development model in China, innovates and cooperates with outstanding domestic and foreign companies, and fully mobilizes domestic and international superior resources to benefit Chinese patients
.
In response to the ever-changing external environment, what Pfizer has to do is to actively integrate domestic and foreign resources and two markets, and accelerate the introduction of first-in-class and best-in-class products on a global scale into China at an unprecedented speed.
Benefit more Chinese patients
.

　　While focusing on the rapid introduction of innovative products into the Chinese market, Pfizer is also committed to promoting the accessibility and affordability of high-quality innovative medicines to patients
.
Carry out "cross-industry and cross-field" cooperation with partners in the fields of Internet healthcare and commercial insurance, explore innovative access paths, innovate multi-party co-payment models, etc.
, to promote the creation of a multi-level medical security system, and ultimately bring dividends to patients
.
Peng Zhenke further explained: “China is one of the largest and most important pharmaceutical markets in the world today
.
A series of important government-led reforms are aimed at optimizing medical services, including increasing the accessibility of innovative drugs
.
Pfizer and Hainan Boao Lecheng take the lead The district administration has carried out in-depth cooperation to speed up the entry of unlisted innovative drugs into China, so that more patients in need can use Pfizer's global innovative drugs in the first time and with greater assurance
.
"

　　It is worth mentioning that not long ago, Peng Zhenke once again served as the chairman of the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment.
Regarding this new appointment, Peng Zhenke said that he will actively promote innovation, intellectual property protection, and market promotion.
Work in the four areas of access and compliance, support the upgrading and innovation of the pharmaceutical industry including China's pharmaceutical reform, continue to introduce innovative products for Chinese patients, and maintain healthy and healthy compliance while actively improving patient access The environment contributes to the sustainable development of the medical and health industry
.